Exhibit 99.1 (c)
FIRST CHINA PHARMACEUTICAL GROUP LIMITED
INTERIM BALANCE SHEETS
(Stated in US Dollars)
| | | | | As of | |
| | | | | June 30, | |
| | Notes | | | 2010 | |
| | | | | $ | |
| | | | | | |
ASSETS | | | | | | |
Current Assets | | | | | | |
Cash and cash equivalents | | | | | | 1,305 | |
Restricted cash | | | 2 | (e) | | | - | |
| | | | | | | | |
Total current assets | | | | | | | 1,305 | |
| | | | | | | | |
Long-term Investment, net | | | 6 | | | | 294,470 | |
| | | | | | | | |
TOTAL ASSETS | | | | | | | 295,775 | |
| | | | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | |
Current Liabilities | | | | | | | | |
Short-term borrowings | | | 7 | | | | - | |
Other payable and accrued liabilities | | | 8 | | | | 295,883 | |
Income tax payable | | | | | | | - | |
| | | | | | | | |
Total Current Liabilities | | | | | | | 295,883 | |
| | | | | | | | |
TOTAL LIABILITIES | | | | | | | 295,883 | |
| | | | | | | | |
COMMITMENTS AND CONTINGENCIES | | | 13 | | | | - | |
| | | | | | | | |
STOCKHOLDERS’ EQUITY | | | | | | | | |
Common stock | | | 10 | | | | 1,285 | |
Authorized, issued and outstanding: | | | | | | | | |
10,000 common shares, par value HK$1 per share | | | | | | | | |
Retained earnings | | | | | | | (1,393 | ) |
Accumulated other comprehensive income | | | | | | | | |
- foreign currency translation adjustments | | | | | | | - | |
| | | | | | | | |
TOTAL STOCKHOLDER’S EQUITY | | | | | | | (108 | ) |
| | | | | | | | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | 295,775 | |
FIRST CHINA PHARMACEUTICAL GROUP LIMITED
INTERIM STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Stated in US Dollars)
| | | | | Three months ended | | | Six months ended | |
| | | | | June 30, | | | June 30, | |
| | Notes | | | 2010 | | | 2010 | |
| | | | | $ | | | $ | |
| | | | | | | | | | |
Net sales | | | | | | | - | | | | - | |
Costs of sales | | | | | | | - | | | | - | |
| | | | | | | | | | | | |
Gross profit | | | | | | | - | | | | - | |
Selling expenses | | | | | | | - | | | | - | |
Administrative expenses | | | | | | | (59 | ) | | | (59 | ) |
Depreciation and amortization | | | | | | | - | | | | - | |
Other (losses)/gains- | | | | | | | - | | | | - | |
Other operating expenses | | | | | | | - | | | | - | |
| | | | | | | | | | | | |
Income from operations | | | | | | | (59 | ) | | | (59 | ) |
Interest income | | | | | | | - | | | | - | |
Interest expense | | | | | | | (49 | ) | | | (49 | ) |
| | | | | | | | | | | | |
Income before tax | | | | | | | (108 | ) | | | (108 | ) |
Income tax | | | | | | | - | | | | - | |
| | | | | | | | | | | | |
Net income | | | | | | | (108 | ) | | | (108 | ) |
Other comprehensive income | | | | | | | | | | | | |
- foreign currency translation adjustments | | | | | | | - | | | | - | |
| | | | | | | | | | | | |
Comprehensive income | | | | | | | (108 | ) | | | (108 | ) |
FIRST CHINA PHARMACEUTICAL GROUP LIMITED
INTERIM STATEMENTS OF SHAREHOLDERS’ EQUITY
(Stated in US Dollars)
| | Common stock | | | Additional paid-in | | | Retained | | | | |
| | Shares | | | Amount | | | capital | | | earnings | | | Total | |
| | | | | $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | | | | |
Balance, April 29, 2010 (Incorporation date) | | | 10,000 | | | | 1,285 | | | | - | | | | - | | | | 1,285 | |
Net income | | | - | | | | - | | | | - | | | | (108 | ) | | | (108 | ) |
Deemed distribution of dividend | | | - | | | | - | | | | - | | | | (1285 | ) | | | (1285 | ) |
| | | | | | | | | | | | | | | | | | | | |
Balance, June 30, 2010 | | | 10,000 | | | | 1,285 | | | | - | | | (1,393) | | | | (108 | ) |
FIRST CHINA PHARMACEUTICAL GROUP LIMITED
INTERIM STATEMENT OF CASH FLOWS
(Stated in US Dollars)
| | From the date of incorporation | |
| | to June 30, | |
| | 2010 | |
| | $ | |
| | | |
Cash Flows from Operating Activities | | | |
Net income | | | (108 | ) |
Adjustments to reconcile net income to net cash provided by operating activities: | | | | |
Depreciation and amortization | | | - | |
Changes in operating assets and liabilities: | | | | |
Due from (to) a related party | | | (1,285 | ) |
Other payables and accrued liabilities | | | 295,883 | |
| | | | |
Net cash used in operating activities | | | 294,490 | |
| | | | |
Cash Flows from Investing Activities | | | | |
Long-term Investment | | | (294,470 | ) |
| | | | |
Net cash used in investing activities | | | (294,470 | ) |
| | | | |
Cash flows from financing activities | | | | |
Capital Contribution | | | 1,285 | |
Decrease (increase) in restricted cash | | | - | |
| | | | |
Net cash provided by (used in) financing activities | | | 1,285 | |
| | | | |
Effect of foreign currency translation on cash and cash | | | | |
equivalents | | | - | |
| | | | |
Net decrease in cash and cash equivalents | | | 1,305 | |
| | | | |
Cash and cash equivalents - beginning of period | | | - | |
| | | | |
Cash and cash equivalents - end of period | | | 1,305 | |
| | | | |
Supplemental disclosures for cash flow information: | | | | |
| | | | |
Cash paid for: | | | | |
Interest | | | - | |
Income taxes | | | - | |